This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Alamifovir
- DrugBank Accession Number
- DB06368
- Background
Alamifovir is an antiviral agent specific for HBV.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Alamifovir (DB06368)
- Weight
- Average: 575.42
Monoisotopic: 575.082695914 - Chemical Formula
- C19H20F6N5O5PS
- Synonyms
- Alamifovir
- External IDs
- LY 582563
- LY-582563
- LY582563
- MCC 478
- MCC-478
Pharmacology
- Indication
Investigated for use/treatment in hepatitis (viral, B).
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Alamifovir is a purine nucleotide analogue prodrug that shows potent activity against wild type and lamivudine resistant hepatitis B virus in preclinical studies.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 0N739K2A8A
- CAS number
- 193681-12-8
- InChI Key
- VDBGPMJFHCJMOL-UHFFFAOYSA-N
- InChI
- InChI=1S/C19H20F6N5O5PS/c1-32-12-2-4-13(5-3-12)37-16-14-15(28-17(26)29-16)30(10-27-14)6-7-33-11-36(31,34-8-18(20,21)22)35-9-19(23,24)25/h2-5,10H,6-9,11H2,1H3,(H2,26,28,29)
- IUPAC Name
- bis(2,2,2-trifluoroethyl) [(2-{2-amino-6-[(4-methoxyphenyl)sulfanyl]-9H-purin-9-yl}ethoxy)methyl]phosphonate
- SMILES
- COC1=CC=C(SC2=C3N=CN(CCOCP(=O)(OCC(F)(F)F)OCC(F)(F)F)C3=NC(N)=N2)C=C1
References
- General References
- Chan C, Abu-Raddad E, Golor G, Watanabe H, Sasaki A, Yeo KP, Soon D, Sinha VP, Flanagan SD, He MM, Wise SD: Clinical pharmacokinetics of alamifovir and its metabolites. Antimicrob Agents Chemother. 2005 May;49(5):1813-22. [Article]
- Soon DK, Lowe SL, Teng CH, Yeo KP, McGill J, Wise SD: Safety and efficacy of alamifovir in patients with chronic hepatitis B virus infection. J Hepatol. 2004 Nov;41(5):852-8. [Article]
- External Links
- PubChem Compound
- 213052
- ChemSpider
- 429846
- BindingDB
- 50115494
- ChEMBL
- CHEMBL106502
- ZINC
- ZINC000003964493
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.164 mg/mL ALOGPS logP 3.06 ALOGPS logP 4.24 Chemaxon logS -3.5 ALOGPS pKa (Strongest Acidic) 16.4 Chemaxon pKa (Strongest Basic) 4.26 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 7 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 123.61 Å2 Chemaxon Rotatable Bond Count 14 Chemaxon Refractivity 122.07 m3·mol-1 Chemaxon Polarizability 46.56 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9266 Blood Brain Barrier + 0.9326 Caco-2 permeable - 0.5808 P-glycoprotein substrate Substrate 0.5474 P-glycoprotein inhibitor I Inhibitor 0.5618 P-glycoprotein inhibitor II Non-inhibitor 0.573 Renal organic cation transporter Non-inhibitor 0.5564 CYP450 2C9 substrate Non-substrate 0.9176 CYP450 2D6 substrate Non-substrate 0.7962 CYP450 3A4 substrate Non-substrate 0.544 CYP450 1A2 substrate Non-inhibitor 0.5117 CYP450 2C9 inhibitor Non-inhibitor 0.5386 CYP450 2D6 inhibitor Non-inhibitor 0.8086 CYP450 2C19 inhibitor Non-inhibitor 0.5251 CYP450 3A4 inhibitor Inhibitor 0.7029 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.7159 Ames test Non AMES toxic 0.5503 Carcinogenicity Non-carcinogens 0.8415 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 2.6199 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.839 hERG inhibition (predictor II) Inhibitor 0.639
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at March 19, 2008 16:27 / Updated at February 21, 2021 18:52